Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) Study.

Ramandip GrewalSarah A BuchanLena NguyenSharifa NasreenPeter C AustinKevin A BrownJonathan GubbayNelson LeeKevin L SchwartzMina TadrousKumanan WilsonSarah E Wilson Jeffrey C Kwong

Published in: The Journal of infectious diseases (2023)

We estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged ≥50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar, strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
early onset
systematic review
binding protein
respiratory syndrome coronavirus
drug induced
metabolic syndrome
network analysis